Allergan Plc (AGN)

158.96
NYSE : Health Technology
Prev Close 160.93
Day Low/High 158.31 / 161.15
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.81M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 52.79B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.81%)

Latest News

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

Aegon Reports First Half 2019 Results

Aegon Reports First Half 2019 Results

Net income increases to EUR 618 million reflecting realized gains and lower other charges ● Underlying earnings decrease by 5% to EUR 1,010 million, reflecting lower fee income as a result of lower average asset balances in the US, and investments in the...

Evolus Could See Breakout Soon

Evolus Could See Breakout Soon

EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.

Lard Friese To Succeed Alex Wynaendts As Aegon's CEO

Lard Friese To Succeed Alex Wynaendts As Aegon's CEO

Aegon announces that its Supervisory Board intends to propose the appointment of Lard Friese as Chief Executive Officer to the Annual General Meeting of Shareholders.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.

Allergan Reports Second Quarter 2019 Financial Results

Allergan Reports Second Quarter 2019 Financial Results

- Q2 2019 GAAP Net Revenues of $4.09 Billion -

A Timeline of Botox's History

A Timeline of Botox's History

A timeline of how Botox became one of the most popular medical beauty procedures.

Dow Rebound?, Disney Reports, Barneys Files Chapter 11 - 5 Things You Must Know

Dow Rebound?, Disney Reports, Barneys Files Chapter 11 - 5 Things You Must Know

U.S. stock futures rise Tuesday, following Wall Street's worst day of the year, as China attempts to ease trade tensions with the U.S., Walt Disney to report earnings Tuesday; Barneys New York files for bankruptcy protection.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Disney, Uber, Lyft and More - Earnings to Watch in the Week Ahead

Disney, Uber, Lyft and More - Earnings to Watch in the Week Ahead

While you may think earnings season is winding down, we still got quite a bit left to go ... here are key companies to keep an eye on the week of August 5, 2019.

Aegon Completes Share Buyback Program

Aegon Completes Share Buyback Program

Aegon has completed the share buyback program announced on June 19, 2019. This program neutralized the dilutive effect of the 2018 final dividend paid in shares.

Allergan To Report Second Quarter 2019 Financial Results

Allergan To Report Second Quarter 2019 Financial Results

DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign

Actress encourages women to take active roles in their reproductive health, including researching birth control options

What to Watch for Earnings In the Second Half of 2019

What to Watch for Earnings In the Second Half of 2019

Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants And Tissue Expanders

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants And Tissue Expanders

-- Global Action Follows Notification of Updated Safety Information from the U.S.

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.

Allergan Declares Third Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

Allergan Declares Third Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

- Dividend to be Paid on September 13, 2019 -

Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

First Biosimilar Avastin® and Herceptin® Products to Launch in the United States

Hagens Berman: Federal Judge Greenlights Class-Action Antitrust Lawsuit Against Allergan Subsidiaries For Loestrin 24, Minastrin And Generics

Hagens Berman: Federal Judge Greenlights Class-Action Antitrust Lawsuit Against Allergan Subsidiaries For Loestrin 24, Minastrin And Generics

A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman.

U.S. FDA Accepts Allergan's New Drug Application For Bimatoprost Sustained-Release In Patients With Open-Angle Glaucoma Or Ocular Hypertension

U.S. FDA Accepts Allergan's New Drug Application For Bimatoprost Sustained-Release In Patients With Open-Angle Glaucoma Or Ocular Hypertension

-- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release --

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, BPFH, TRTN Downgrades: HMG, PIH Initiations: DHXM Read on to get TheStreet Quant Ratings' detailed report:

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

TheStreet Quant Rating: C (Hold)